Improved understanding of new malaria treatment
Drugs based on the substance artemisinin (derived from a Chinese herb) are now the main hope in the battle against malaria. It is often best to give malarial drugs rectally. Focusing on the rectal administration of one artemisinin derivative (artesunate), researchers have added to what is known about its pharmokinetics – i.e. the way in which it is absorbed and processed by the body. They established that artesunate is sufficiently well absorbed via the rectal route in most patients to make artesunate suppositories a promising first-line treatment for moderately severe malaria. However, they also noted that patients do vary in how well they process the drug.
Citation: Simpson JA, Agbenyega T, Barnes KI, Di Perri G, Folb P, et al. (2006) Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med 3(11): e444.
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx/doi.org/10.1371/journal.pmed.0030444
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-11-simpson.pdf
CONTACT:
Julie Simpson
The University of Melbourne
Department of Public Health
Level 2, 723 Swanston Street
Carlton, Victoria
Australia, 3053
+61-3-9533-6651
julieas@unimelb.edu.au
Potential new drug in war against tuberculosis
The number of cases of tuberculosis continues to rise worldwide and there are major problems with resistance to the drugs used to treat it. Japanese scientists have identified a compound which attacks the cell walls of the organism that causes the disease, Mycobacterium tuberculosis. They now report their laboratory and animal studies, which suggest the new compound (OPC-67683) has potential as a treatment for the disease. Clinical studies with patients are now needed.
Citation: Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, et al. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3(11): e466.
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx/doi.org/10.1371/ journal.pmed.0030466
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-11-matsumoto.pdf
CONTACT:
Makoto Matsumoto
Otsuka Pharmaceutical Co.Ltd.
Microbiological Research Institute
463-10 Kagasuno Kawauchi-cho
Tokushima, 771-0192
Japan
+81-88-665-2126
m_matsumoto@research.otsuka.co.jp
* * * * * * * * EMBARGO: MONDAY, 27 November, 5 P.M. PST * * * * * * *
About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org
About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org
PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.
All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere—to read, download, redistribute, include in databases, and otherwise use—subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.
Journal
PLoS Medicine